ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

"For ctDNA-positive patients, escalation treatment will be administrated~1. Ivonescimab: Intravenous infusion (IV), 20 mg/kg, Day 1, every 3 weeks (Q3W);~2. Docetaxel: IV, 75 mg/m², Day 1, Q3W (The investigator may adjust the chemotherapy dose and schedule based on the patient's tolerance during treatment.)~All enrolled participants will continue treatment until one of the following occurs, whichever comes first:~* The investigator determines that there is no longer clinical benefit (based on imaging assessments and clinical status)~* Unacceptable toxicity~* Completion of 24 months of treatment~* Other discontinuation criteria specified in the protocol are met."

"For ctDNA-positive patients, continuing the original immunotherapy maintenance or immunotherapy combined with chemotherapy~• In the event of clinical progression, consider switching to treatment with Ivonescimab plus docetaxel, administered every 3 weeks."